Drug Type Small molecule drug |
Synonyms Atectura Breezhaler, IND/MF, Indacaterol/mometasone + [8] |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (06 May 2020), |
Regulation- |
Molecular FormulaC26H32N2O5 |
InChIKeyHZHXFIDENGBQFQ-FTBISJDPSA-N |
CAS Registry1000160-96-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | Canada | 06 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mild asthma | Phase 3 | United States | 16 Jan 2017 | |
Mild asthma | Phase 3 | Japan | 16 Jan 2017 | |
Mild asthma | Phase 3 | Bulgaria | 16 Jan 2017 | |
Mild asthma | Phase 3 | Chile | 16 Jan 2017 | |
Mild asthma | Phase 3 | Colombia | 16 Jan 2017 | |
Mild asthma | Phase 3 | Estonia | 16 Jan 2017 | |
Mild asthma | Phase 3 | Germany | 16 Jan 2017 | |
Mild asthma | Phase 3 | Hungary | 16 Jan 2017 | |
Mild asthma | Phase 3 | India | 16 Jan 2017 | |
Mild asthma | Phase 3 | Italy | 16 Jan 2017 |
Phase 2 | 24 | fzirunshcu(ucmontzdzy) = aswsxasftb jaalobcmzk (pdjmcvykfu, 0) View more | - | 27 Jul 2023 | |||
Phase 3 | 3,154 | wwgojqdbyo(aqnuqjrtce) = jvnpdnvayw tlebdmkfug (xoxjzgxgen ) View more | Positive | 01 Aug 2021 | |||
tgdzendfky(nynrtaerfx) = ndiayxinyp zhncsftyda (gflfwokydw ) | |||||||
Phase 3 | 2,216 | rmexpzgrbc(mnwrgbfdnb) = frekypwfqm aqolikvtgx (pyzwcupghg, 0.0162) View more | - | 05 Mar 2020 | |||
Phase 3 | 51 | (QMF-149 150/320 μg) | mfkokshgpt = eefbksflwi ucnmagghjt (jqibltulqc, bmnarhhidl - vltuoweyrt) View more | - | 07 Feb 2020 | ||
(QMF149 150/320 µg) | aaafyvkbzk(algjaipyhj) = bgdpjehgjk dgihzopglg (nougdrrjjb, czdnhmiiai - xrlzszlnmz) View more | ||||||
Phase 3 | 802 | cwnnwhwdoi(ougkohcnhq) = oudkdheicr mrtvtgwqxk (nutrwjsxmo, 0.182) | Positive | 28 Sep 2019 | |||
Phase 3 | 802 | (QMF149 150/80 μg) | juqyszuozv(ajrueoeeyy) = fwlqqgnilr gdcgryloah (ojkxmboflo, 0.0134) View more | - | 12 Sep 2019 | ||
(MF 200 µg) | juqyszuozv(ajrueoeeyy) = lwuxhplfdl gdcgryloah (ojkxmboflo, 0.0134) View more | ||||||
Phase 2 | 629 | zvrunwabjn(nvxgsgydgm): difference = 56, P-Value = <0.001 | Superior | 06 Dec 2018 | |||
salmeterol xinafoate/fluticasone propionate | |||||||
Phase 2 | 1,519 | wbcmcrnxic(iiksiuenmp) = kzpdbthxcm rzjrznnwdt (zneruuyqka ) View more | Positive | 03 Feb 2015 | |||
wbcmcrnxic(iiksiuenmp) = pgmkryrrdx rzjrznnwdt (zneruuyqka ) View more | |||||||
Phase 2 | 629 | (QMF149) | imexbrcjnw(jmeweziako) = rmiruyycqd tqkswaezke (krtlkhigda, 0.0124) View more | - | 17 Nov 2014 | ||
(Salmeterol Xinafoate/Fluticasone Propionate) | imexbrcjnw(jmeweziako) = yulsazhott tqkswaezke (krtlkhigda, 0.0124) View more | ||||||
Not Applicable | 335 | lairmmkmfy(iptqcntvvd) = irnnelbmmy beufgxhnxm (ukusndsqqc ) | Positive | 01 Sep 2014 | |||
lairmmkmfy(iptqcntvvd) = eoovdpbdyd beufgxhnxm (ukusndsqqc ) |